Navigation Links
Covance to Present at Lehman Brothers 11th Annual Global Healthcare Conference
Date:3/18/2008

PRINCETON, N.J., March 18 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) today announced that it will present at the Lehman Brothers 11th Annual Global Healthcare Conference on Wednesday, March 19, 2008 at 2:00 pm ET. Investors may access a live webcast of the presentation at http://www.covance.com. In order to register and download any necessary software, please log on 10 minutes early.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.5 billion, global operations in more than 20 countries, and more than 8,700 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at http://www.covance.com.


'/>"/>
SOURCE Covance Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Covance to Present at Raymond James 29th Annual Institutional Investors Conference
2. Covance to Present at UBS Global Healthcare Services Conference
3. Covance to Present at 26th Annual JPMorgan Healthcare Conference
4. Wendel Barr Appointed Chief Operating Officer of Covance
5. Covance and Care Partner on Rwanda Early Childhood Development Initiative
6. eResearchTechnology, Inc. to Announce Agreement to Acquire the Centralized ECG Business of Covance
7. eResearchTechnology (eRT) Agrees to Acquire the Centralized ECG Business of Covance
8. Covance Agrees to Enter Strategic Relationship with eResearchTechnology to Offer its Clients eRTs Centralized Cardiac Safety Services
9. Covance Elects Dr. Gary E. Costley to Board of Directors
10. Covance to Present at the UBS Global Life Sciences Conference
11. Hologic to Present at Lehman Brothers Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , ... December 05, 2016 , ... ... Plastic Surgery, is excited to announce the arrival of the newest Sciton laser ... with the ability to use tunable non-ablative and ablative wavelengths for exceptional results. ...
(Date:12/5/2016)... ... December 05, 2016 , ... SyncDog, Inc., the leading ... magazine, a leading online tech news platform connecting technology innovators with news, experience, ... explores the state of enterprise mobility security today, and how the SyncDog SentinelSecure™ ...
(Date:12/5/2016)... ... 05, 2016 , ... Worldwise ®, a leading consumer ... kathy ireland® Worldwide for five additional years, announced by Kevin Fick, Worldwise CEO. ... agreement three years ago to design and develop the kathy ireland® Loved Ones™ ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education Resource®, ... International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on February ... are honored to have Amy E. Herman present at this year’s conference, her ...
(Date:12/5/2016)... , ... December 05, 2016 , ... BSI and Brenntag ... United States and Canada for distribution of their natural fruits and beverage ... is an exciting addition to our Life Sciences product portfolio,” said Steve Brauer, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Dec. 5, 2016   Mallinckrodt Pharmaceuticals (NYSE: ... company, today announced that it received a perfect score ... (CEI), a national benchmarking survey and report on corporate ... transgender (LGBT) workplace equality, administered by the Human Rights ... major U.S. businesses which also earned top marks this ...
(Date:12/5/2016)... , Dec. 5, 2016 Special purpose needles are ... such as fluid and cells from organs or lumps and ... and sizes. The global market for special purpose needles is ... In terms of revenue, the global special purpose needles market ... the forecast period (2016–2026) and is expected to be valued ...
(Date:12/5/2016)...   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... 2 clinical study of sotagliflozin, a dual SGLT1 and ... the leading global organization funding type 1 diabetes research. ... trial, which randomized a total of 87 patients, was ... dose of sotagliflozin compared to a placebo control in ...
Breaking Medicine Technology: